about
Beta-blockers for hypertensionBeta-blockers for hypertensionBeta-blockers for hypertensionWhat is good for the circulation also lessens cancer riskMelatonin has multiorgan effectsControversies in stable coronary artery diseaseCardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysisDual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioningBeta-blockers for hypertension.Study design for the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care (IMMEDIATE) Trial: A double-blind randomized controlled trial of intravenous glucose, insulin, and potassium for acute coronaryIs red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection.Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial.Beta-blockers and the treatment of hypertension: it is time to move onThe metabolic vicious cycle in heart failure.The proposed role of plasma NT pro-brain natriuretic peptide in assessing cardiac remodelling in hypertensive African subjectsEfficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes.The red wine hypothesis: from concepts to protective signalling molecules.Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.Metabolic plasticity and the promotion of cardiac protection in ischemia and ischemic preconditioning.Cardiovascular remodelling in coronary artery disease and heart failure.Lifestyle and diet.Tedisamil in coronary disease: additional benefits in the therapy of atrial fibrillation?Old antihypertensives and new diabetes.Angina pectoris: the evolution of concepts.Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion.PKCε promotes cardiac mitochondrial and metabolic adaptation to chronic hypobaric hypoxia by GSK3β inhibition.TNFα protects cardiac mitochondria independently of its cell surface receptors.Hypertension in sub-Saharan African populations.Influence of tumour necrosis factor alpha on the outcome of ischaemic postconditioning in the presence of obesity and diabetes.Controversies in hypertension.Controversies in atrial fibrillation.Controversies in ventricular remodelling.How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis.Metabolic mechanisms in heart failure.The adrenergic-fatty acid load in heart failure.Controversies in the cardiovascular management of type 2 diabetes.Glucose-insulin-potassium revived: current status in acute coronary syndromes and the energy-depleted heart.Exercise-induced myalgia may limit the cardiovascular benefits of statins.Warfarin in non-valvular atrial fibrillation.Cognitive decline: mechanisms and proposed role of the renin-angiotensin-aldosterone system
P50
Q24201511-8BB4DEBB-0182-48F1-A0D0-8EC49BA56D39Q24202812-9A02C2A9-5FCE-478B-B881-C6608DFB9A65Q24243099-BFE16914-DDB2-4FC1-A27E-474B3F82CD17Q26859261-BB2C7DAE-17FB-40FB-9435-ACB4292E2786Q28077901-82E60A84-8523-464B-8F0D-598A8389F462Q28194400-D9349131-DD4C-49F1-BB42-7063327E1962Q28200196-796BCA04-5783-40E7-85DE-D1C770F1E9D7Q28771386-D4AB1469-1569-4B71-918F-8EA325533603Q30238911-28C26A32-9E36-40C9-8D7A-C4CF75D70CA7Q33564586-FFD64DE9-6B12-446C-9E47-35433A7C2890Q34166155-878521E5-6D5F-4977-B91E-AA63E361044DQ34204296-DB553D2E-F3C6-4097-A01A-CDC9D7BE49FFQ34221117-2C3427DB-1D88-430E-B26A-BD2F7D60076BQ34367318-FBFAEA10-6BAA-440C-B96F-DBA16FB6A718Q34561996-B8F1EB19-F27A-41BA-BA4D-4E5E009FCF24Q34573700-F51A81DF-E634-45C9-800B-2596D38A4D50Q34636347-D3AC0D73-9F5D-4DBB-8FB3-662311E85BA6Q34819581-11F1B64B-24F5-43D5-BDBA-5487AC571B2BQ34977067-14DF55EF-3DDC-48CD-AAA5-4963885C4240Q35090566-7269438B-C16B-4A04-A94E-1AFA67BCA1CFQ35109151-AA00AC30-D7DD-4721-871D-F910AED342E8Q35127397-91BCF491-28A3-46FE-806A-30F2DBFED27DQ35838219-46C2A830-FBBA-4AE2-957F-B0B7CEFAE30EQ35892156-7E5B6A66-2253-46B6-9D57-97874B5CD3C9Q36099739-4E4C86D8-C800-4ABF-8C27-2F95B4DB91BCQ36138182-35D9EF54-3EA6-435B-878E-182CD6B6EB6EQ36148170-44621D13-4342-44A4-9816-91CF59399E51Q36332135-47B93441-2E62-4B66-9995-E4FDC019518AQ36355264-C730A93E-B387-47C1-A592-6A8E49263F31Q36368854-1C782222-4E4B-41B0-A4FF-2614AC15D1DAQ36374193-24AC39D6-F33F-4909-97DF-AD1FA60664FFQ36380191-E6DB64DE-3584-483B-B1CB-1B9CFE22766DQ36629674-8AE2DEA5-FF55-4993-A793-3CBEAF20DAA2Q36889876-8319EAEE-CD97-4760-A51F-FA52C2CF9DE3Q37619839-157391E9-D762-4A20-BF56-84961A650D45Q37812197-CE59F350-8F50-4948-8CC4-1C6A3F4C2E0BQ38086415-4E4C7763-9ED4-48A9-A5A2-55556E1C6F4BQ38128190-57D195ED-1CD0-49AE-BA33-4A9FF820B9FAQ38168402-D07915B3-A541-41A9-BC00-99FF6DBF99E2Q38246323-46FC5486-AD82-4A1D-B078-A9E8976242C4
P50
name
Lionel Opie
@ast
Lionel Opie
@en
Lionel Opie
@es
Lionel Opie
@nl
type
label
Lionel Opie
@ast
Lionel Opie
@en
Lionel Opie
@es
Lionel Opie
@nl
altLabel
Lionel H Opie
@en
Lionel H. Opie
@en
prefLabel
Lionel Opie
@ast
Lionel Opie
@en
Lionel Opie
@es
Lionel Opie
@nl